Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia
Conclusions
Our multicenter study provides further evidence for the efficacy of fingolimod in reducing clinical and radiological disease activity in patients with RRMS. The reduction in relapse rate, stabilization of the EDSS score, and improvement in magnetic resonance imaging images were similar to other observational studies conducted in different countries worldwide. Fingolimod seems to be well tolerated for our multiple sclerosis population.
Source: Clinical Neuropharmacology - Category: Neurology Tags: Original Articles Source Type: research
More News: Brain | Disability | Gilenya | Middle East Health | MRI Scan | Multiple Sclerosis | Neurology | Saudi Arabia Health | Study